Skip to content
RushPR News – Lifestyle
Author:
Korro Bio, Inc.
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 19, 2026
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
Korro to Participate in Upcoming Investor Conferences
May 5, 2026
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
April 16, 2026
Korro Announces Oversubscribed $85 Million Private Placement
March 26, 2026
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 12, 2026